Biography and Research Information
OverviewAI-generated summary
Delgado-Calle Jesus is a graduate student at the University of Arkansas for Medical Sciences. Their research focuses on identifying therapeutic targets for multiple myeloma, specifically investigating the role of NOTCH3. In a 2026 publication, Delgado-Calle and collaborators explored the potential of targeting NOTCH3 to eliminate dormant and therapy-resistant multiple myeloma cells. This work involved collaboration with researchers Corey Montgomery, Aric Anloague, and Mattie R. Nester from the University of Arkansas for Medical Sciences, who have co-authored publications with Delgado-Calle.
Metrics
- Publications: 2
Selected Publications
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
Collaboration Network
Top Collaborators
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
Similar Researchers
Based on overlapping research topics